Novel intravaginal ring shows promise in HIV prevention
October 16, 2012 in HIV & AIDS
A new 90-day intravaginal ring has been developed—that for the first time—enables the long-lasting vaginal delivery of tenofovir (TFV), the only topical prophylactic shown to be effective at reducing the sexual transmission of human immunodeficiency virus (HIV) when formulated in a short-lasting gel. This research is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Chicago, Ill., Oct. 14 – 18.
Lead researcher Patrick Kiser and colleagues from the University of Utah, in collaboration with CONRAD, a leading reproductive health research organization, created a novel reservoir ring composed in part of plastic tubing that absorbs water when placed in the body. Conventional ring technology, developed in the 1970s, is inadequate in delivering water-soluble drugs such as TFV. This new design allows for large quantities of TFV to be delivered for up to 90 days, at doses expected to prevent HIV infection.
"We anticipate that this next-generation ring will be able to release a spectrum of drugs that currently cannot be delivered due to limitations of standard technology," said Kiser, who led development of the ring at the University of Utah. "This ring is a breakthrough design because it is highly adaptable to almost any drug; the amount of drug delivered each day is the same and the release rate can be modified easily if needed."
Kiser's research group shows that the vaginal concentration of TFV in sheep using the new ring is similar to or exceeds that of a short-lasting TFV vaginal gel that was proven to be clinically effective at reducing the risk of HIV acquisition in women. This ring can also be readily modified to deliver an anti-HIV agent and a contraceptive at the same time, making it a multi-purpose prevention technology. Work is in progress to do just that, as the group has recently developed a ring to co-deliver TFV and the hormonal contraceptive levonorgestrel (LNG).
Provided by
American Association of Pharmaceutical Scientists
-
Anti-HIV vaginal gel promising protection in Africa, SE asia
Apr 20, 2011 |
not rated yet |
0
-
Anti-HIV vaginal ring can prevent virus transmission: animal study
Sep 05, 2012 |
not rated yet |
0
-
Study of anti-AIDS vaginal ring begins in Africa
Jul 24, 2012 |
not rated yet |
0
-
Microbicides that do more than gel: Vaginal rings, tablets and films
May 24, 2010 |
not rated yet |
0
-
AIDS experts: Women need more help in AIDS battle
Jul 25, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Fecal microbiota tx feasible for recurrent C. difficile in HIV
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
HIV & AIDS
16 hours ago |
not rated yet |
0
Canada lifts ban on gay men donating blood
Canadian health authorities lifted Wednesday what was effectively a ban on gay men giving blood, announcing new rules making men who have not had sex with men in the past five years eligible.
HIV & AIDS
18 hours ago |
not rated yet |
1
AIDS scientists optimistic of AIDS cure, for some
Top AIDS scientists were optimistic Wednesday of finding a cure for the disease that has claimed 30 million lives—but said it might not work for all people.
HIV & AIDS
21 hours ago |
not rated yet |
0
Integrating mental health care into HIV care
The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...
HIV & AIDS
May 21, 2013 |
not rated yet |
0
After a decade, global AIDS program looks ahead
(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...
HIV & AIDS
May 21, 2013 |
not rated yet |
0
Pay attention: How we focus and concentrate
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
New discovery in fight against deadly meningococcal disease
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
Are kids who take music lessons different from other kids?
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease
Studying the networks of connections in the brains of people affected by schizophrenia, bipolar disease or depression has allowed Dr. Peter Williamson, from Western University, to gain a better understanding of the biological ...
New imaging techniques used to help patients suffering from epilepsy
New techniques in imaging of brain activity developed by Jean Gotman, from McGill University's Montreal Neurological Institute, and his colleagues lead to improved treatment of patients suffering from epilepsy. The combination ...
Study reveals active site of enzyme linked to stuttering
(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...